Despite ongoing challenges in the clinical application of PLK1 and p53 targeted therapies for breast cancer, BI2536 does not adversely affect cardiomyocytes but significantly impairs the proliferation of primary fibroblasts (Steegmaier et al., 2007). Here, PLK1 is linked to breast carcinoma.